BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Xoft Inc. Electronic Brachytherapy CME Industry Satellite Symposium to Be Launched at ASTRO


10/23/2007 9:15:15 AM

FREMONT, Calif., Oct. 23 /PRNewswire/ -- Xoft, Inc., developer of the Axxent(R) Electronic Brachytherapy System, a proprietary cancer treatment platform, announced that it has awarded an educational grant for an Industry Satellite Symposium focused on Electronic Brachytherapy at the upcoming American Society for Therapeutic Radiology and Oncology (ASTRO) meeting. The symposium, scheduled for October 28, 2007, will focus on Electronic Brachytherapy (EBT) as an emerging technology for the treatment of early stage breast cancer. The grant recipient and symposium organizer is Northwest Imaging Forums, a developer of continuing medical education curriculum.

The program, "Electronic Brachytherapy: Putting the Accent on Access," is intended to educate radiation oncology professionals about this novel new technology that utilizes a miniature 50kv x-ray source in high dose rate (HDR) brachytherapy procedures. It will provide a comparison of EBT to conventional iridium sources that it is designed to mimic and potential clinical advantages of this electronic x-ray source. For example, because EBT dose penetration levels are significantly lower than traditional isotopes, and because the source is electronic, the room shielding requirements are minimal and the treatment can be delivered in a variety of clinical environments with the therapist in the treatment room, offering patients emotional and physical comfort.

"Because Electronic Brachytherapy represents a new method for delivering radiation therapy for the treatment of early stage breast cancer, education is essential to support clinical adoption," said Vivek Mehta MD, director, Center for Advanced Targeted Radiotherapies at the Swedish Cancer Institute in Seattle and symposium chairman and moderator. "This technology appears to offer a number of clinical advantages which could make accelerated partial breast irradiation treatment more accessible to the large population of women with breast cancer who currently do not receive any form of radiation therapy treatment due to limited access. This CME course gives radiation oncology professionals the information and case reviews needed to fully evaluate the technology and its potential benefits."

The faculty also includes Adam Dickler, MD, radiation oncologist, Little Company of Mary Hospital in Evergreen Park, IL., Kenneth Haile, MD, radiation oncologist, Wellstar Hospital in Marietta, GA, and David E. Wazer, MD, professor and chairman of Radiation Oncology, Brown University School of Medicine in Providence, RI.

Educational objectives include comparing the Electronic Brachytherapy x-ray source to iridium and other radioactive isotopes currently used in brachytherapy procedures; reviewing various applicator devices and certain patient criteria for appropriate candidates for EBT; and evaluating and comparing actual clinical case studies utilizing EBT. In addition, physician attendees will learn about the clinical experience with EBT to date as well as potential future applications of the technology. For physicians, this educational activity is certified for a maximum of 1.5 AMA PRA Category 1 Credits. This program has also been submitted for approval of 1.5 hours of Category A CE credit (evidence of continuing education) for ARRT technologists by the American Society of Radiologic Technologists (ASRT) and has been submitted for accreditation approval to the Medical Dosimetrist Certification Board (MDCB).

This CME activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of The Institute for Medical Studies (IMS) and Northwest Imaging Forums (NIF). IMS is accredited by the ACCME to provide continuing medical education for physicians.

About Xoft, Inc.

Xoft is developing leading-edge new technologies for the practice of radiation oncology through Electronic Brachytherapy, which utilizes proprietary miniaturized x-ray tube technology. The Axxent(R) Electronic Brachytherapy System, Xoft's first treatment system, is currently being used in Accelerated Partial Breast Irradiation (APBI) for the treatment of early-stage breast cancer. This solution provides a therapeutic dose of intracavitary radiation directly to the region at risk without the complex handling and resource logistics necessary when performing brachytherapy using radioactive isotopes.

Axxent is a registered trademark of Xoft, Inc.

CONTACT: Chris K. Joseph, +1-510-339-2293, chris@ckjcomm.com, for Xoft,
Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES